Order five or more vials of the same Retatrutide size and you'll receive an automatic 15% discount
Side Effects & Safety Nausea most common (~33% at high doses), dose-dependent, typically improves over time GI effects vomiting, diarrhea, constipation, slowed gastric emptying (GLP-1 class effects) Heart rate changes transient increases observed in trials, peaked at 24 weeks then declined Injection site reactions mild redness or irritation Gallbladder risk rapid weight loss increases gallstone risk (common with any rapid weight loss method) No major safety signals in 48-week trial up to 12 mg weekly At community doses (1.5 mg/week), side effects are notably milder than high-dose trial groups Dosage Chart This dosage chart consolidates the doses reported in published Phase 2 trials and self-reported community protocols, expressed in milligrams (mg) and converted to units on a standard 100-unit / 1mL insulin syringe
5,19 Like any medication, GLP-1RAs may have side effects, including nausea, vomiting, diarrhea, and injection site reactions
Across these systems, early clinical or translational setbacks were frequently interpreted as evidence of flawed biology rather than limitations in pharmacologic engineering, dosing paradigms, or endpoint selection
